A
Adel R. Rizkala
Researcher at Novartis
Publications - 40
Citations - 9772
Adel R. Rizkala is an academic researcher from Novartis. The author has contributed to research in topics: Heart failure & Sacubitril, Valsartan. The author has an hindex of 24, co-authored 36 publications receiving 6960 citations.
Papers
More filters
Journal ArticleDOI
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
John J.V. McMurray,Milton Packer,Akshay S. Desai,Jianjian Gong,Martin Lefkowitz,Adel R. Rizkala,Jean L. Rouleau,Victor Shi,Scott D. Solomon,Karl Swedberg,Michael R. Zile,Abstr Act +11 more
TL;DR: LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure and decreased the symptoms and physical limitations of heart failure.
Journal ArticleDOI
Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction
Scott D. Solomon,John J.V. McMurray,Inder S. Anand,Junbo Ge,Carolyn S.P. Lam,Aldo P. Maggioni,Felipe Martinez,Milton Packer,Marc A. Pfeffer,Burkert Pieske,Margaret M. Redfield,Jean L. Rouleau,Dirk J. van Veldhuisen,Faiez Zannad,Michael R. Zile,Akshay S. Desai,Brian Claggett,Pardeep S. Jhund,Sergey Boytsov,Josep Comín-Colet,John G.F. Cleland,Hans-Dirk Düngen,Hans-Dirk Düngen,Eva Goncalvesova,Tzvetana Katova,José Francisco Kerr Saraiva,Małgorzata Lelonek,Béla Merkely,Michele Senni,Sanjiv J. Shah,Jingmin Zhou,Adel R. Rizkala,Jianjian Gong,Victor Shi,Martin Lefkowitz +34 more
TL;DR: Sacubitril-valsartan did not result in a significantly lower rate of total hospitalizations for heart failure and death from cardiovascular causes among patients with heart failureand an ejection fraction of 45% or higher, and among 12 prespecified subgroups, there was suggestion of heterogeneity with possible benefit in patients with lower ejection fractions and in women.
Journal ArticleDOI
Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure
Milton Packer,John J.V. McMurray,Akshay S. Desai,Jianjian Gong,Martin Lefkowitz,Adel R. Rizkala,Jean L. Rouleau,Victor Shi,Scott D. Solomon,Karl Swedberg,Michael R. Zile,Karl Andersen,Juan Luis Arango,J. Malcolm O. Arnold,Jan Belohlavek,Michael Böhm,Sergey Boytsov,Lesley J. Burgess,Walter Cabrera,Carlos Calvo,Chen Huan Chen,Andrej Dukát,Yan Carlos Duarte,Andrejs Erglis,Michael Fu,Efrain Gomez,Angel Gonzàlez-Medina,Albert A. Hagège,Jun Huang,Tzventana Katova,Songsak Kiatchoosakun,Kee-Sik Kim,Ömer Kozan,Edmundo Alfredo Bayram Llamas,Felipe Martinez,Béla Merkely,Ivan Mendoza,Arend Mosterd,Marta Negrusz-Kawecka,Keijo Peuhkurinen,Felix José Alvarez Ramires,Jens Refsgaard,Arvo Rosenthal,Michele Senni,Antonio S. Sibulo,José Silva-Cardoso,Iain B. Squire,Randall C. Starling,John R. Teerlink,Johan Vanhaecke,Dragos Vinereanu,Raymond Ching-Chiew Wong +51 more
TL;DR: Angiotensin-neprilysin inhibition prevents the clinical progression of surviving patients with heart failure more effectively than angiotens in-converting enzyme inhibition.
Journal ArticleDOI
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin- converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
John J.V. McMurray,Milton Packer,Akshay S. Desai,Jim Gong,Martin Lefkowitz,Adel R. Rizkala,Jean L. Rouleau,Victor Shi,Scott D. Solomon,Karl Swedberg,Michael R. Zile +10 more
TL;DR: The PARADIGM-HF trial as discussed by the authors evaluated the effect of angiotensin receptor neprilysin inhibitors (ARNIs) on the risk of heart failure in patients with chronic heart failure.
Journal ArticleDOI
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
Akshay S. Desai,John J.V. McMurray,Milton Packer,Karl Swedberg,Jean L. Rouleau,Fabian Chen,Jianjian Gong,Adel R. Rizkala,Abdel Brahimi,Brian Claggett,Peter V. Finn,Loren Howard Hartley,Jiankang Liu,Martin Lefkowitz,Victor Shi,Michael R. Zile,Scott D. Solomon +16 more
TL;DR: LCZ696 was superior to enalapril in reducing both sudden cardiac deaths and deaths from worsening heart failure, which accounted for the majority of cardiovascular deaths.